Altimmune, Inc.

46 Days Left

Class Action Period:
December 01, 2023 - April 26, 2024

Lead Plaintiff Deadline:
July 05, 2024

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Allegations

The filed complaint alleges that Altimmune, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Altimmune overstated the potential for its lead product candidate, pemvidutide, to stand out from competing glucagon-like peptide-1 agonists based on the drug’s efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial results were less significant to pemvidutide’s clinical, commercial, and competitive prospects than Defendants had led investors to believe; (iii) as a result of all the foregoing, defendants had overstated Altimmune’s prospects for finding a strategic partner to develop pemvidutide; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Altimmune purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Altimmune during the relevant time frame, you have until July 05, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.